Deal Details:

• QIP helped achieving dual objectives of raising growth capital for funding Company’s CAPEX plans as well as Minimum Public Shareholding (MPS) norms
• Offering received an overwhelming response from investors – a testimony to Dhanuka Group’s ability to successfully turnaround Orchid’s business
• ~90% of the book was allocated to ‘Long Only’ Investors
• The deal further strengthens our ability to provide best-in-class advisory services to SaaS and new-age businesses

Contribution:

• With this QIP, Nuvama has successfully closed the 2nd transaction for Orchid Pharma being the “Banker of Choice”
• As the left-lead banker, hand-held the Company in end-to-end execution, swift regulatory approvals, thereby ensuring timely launch
• Nuvama garnered participation from a diverse investor set including Marquee ‘Long Only’ FII and DII investors
• The deal further strengthens our ability to provide best-in-class advisory services to SaaS and new-age businesses

About:

• Orchid Pharma Ltd. is an active pharmaceutical ingredients (“API”) manufacturing company with the widest portfolio of cephalosporin APIs along with a few veterinary products, both sterile and oral, selling under a b2b model in over 40 countries.